Integration of clinical information and molecular biology profile -Endeavor of SCRUM-Japan-.
In recent years, the cancer therapy based on the biomarker has been clinically introduced in colorectal cancer. Furthermore, the therapeutic development for the colorectal cancer patients corresponding to gene alteration, such as BRAF gene mutation and microsatellite instability(MSI), are underway. Although the development of the novel treatments according to biomarkers is urgent the fragmentation of the patient population by biomarker have caused various problems in the treatment development. To accelerate the development of therapeutic agents for small population, we conduct a nationwide genome screening project'SCRUM- Japan'.